NCT05020730View on ClinicalTrials.gov

Trial to Determine the Immunomodulatory Activity of PTM-001 in Patients With Hidradenitis Suppurativa

PHASE2UnknownINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

May 5, 2022

Primary Completion Date

December 31, 2023

Study Completion Date

June 30, 2024

Conditions
Hidradenitis Suppurativa
Interventions
DRUG

PTM-001

PTM-001 (400 mg) every day for 12 weeks

DRUG

Placebo

Matching placebo every day for 12 weeks

Trial Locations (3)

45229

RECRUITING

Phoenicis Investigative Site, Cincinnati

94063

RECRUITING

Phoenicis Investigative Site, Redwood City

01655

RECRUITING

Phoenicis Investigative Site, Worcester

Sponsors
All Listed Sponsors
lead

Phoenicis Therapeutics

INDUSTRY